Search...
Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli
I'm PortAI, I can summarize articles.
Apellis (APLS) announced positive Phase 3 results for its kidney disease treatment, Empaveli, published in the New England Journal of Medicine. The study showed a 68% reduction in proteinuria at Week 26, stabilization of kidney function, and reduced C3 staining. Results were consistent across adults and adolescents, including post-transplant patients. Empaveli is FDA-approved for patients 12 and older. Shares rose over 1% in after-hours trading.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments